Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Multiple myeloma
BCMA and GPRC5D CAR-T cells and bispecifics, and what is left after triple-class exposure.
Live from ClinicalTrials.gov, fetched 2026-11-12 13:38 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
38%
226 trial titles name relapsed, refractory or recurrent disease
Led by industry
35%
210 trials with a company as lead sponsor
106 of the 600 multiple myeloma trials are Phase 3; 37 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of multiple myeloma (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 183 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Locally advanced1L · Maintenance1L · Relapsed or refractory2L+2L+ · Relapsed or refractoryAdvanced or metastaticBCMABCMA · 1LBCMA · 2L+BCMA · Relapsed or refractoryCD38CD38 · Relapsed or refractoryGPRC5DGPRC5D · 1L · MaintenanceGPRC5D · MaintenanceGPRC5D · Relapsed or refractoryLocally advancedMaintenanceRelapsed or refractoryt(11;14) · 1Lt(11;14) · Relapsed or refractoryUntagged
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Fludarabine City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT03710421, NCT06615479, NCT06940297, NCT07759102 +4 |
| Selinexor Karyopharm Therapeutics Inc | Relapsed or refractory | Other or not recognised | Ph3 | NCT04414475, NCT04925193, NCT04756401, NCT06822972 +4 |
| Etentamig AbbVie | Relapsed or refractory | Other or not recognised | Ph3 | NCT05650632, NCT06158841, NCT05259839, NCT07728188 +1 |
| fludarabine phosphate City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT01163357, NCT06066359, NCT05092451, NCT02861417 +1 |
| Mycophenolate Mofetil M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT02861417, NCT05805605, NCT03246906, NCT01231412 |
| Sirolimus National Cancer Institute (NCI) | Relapsed or refractory | Other or not recognised | Ph3 | NCT06876142, NCT01163357, NCT03246906, NCT01231412 |
| BMS-986393 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Relapsed or refractory | Other or not recognised | Ph3 | NCT06615479, NCT06121843 |
| Cyclosporine Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT03246906, NCT01231412 |
| Diphenhydramine Sanofi | Relapsed or refractory | Other or not recognised | Ph3 | NCT06356571, NCT05405166 |
| IBI3003 Fortvita Biologics (USA)Inc. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07336472, NCT07623798 |
| JNJ-79635322 Janssen Research & Development, LLC | Relapsed or refractory | Other or not recognised | Ph3 | NCT07266441, NCT07518186 |
| Melphalan National Cancer Institute (NCI) | Relapsed or refractory | Other or not recognised | Ph3 | NCT00114101, NCT01054196 |
| Montelukast Sanofi | Relapsed or refractory | Other or not recognised | Ph3 | NCT06356571, NCT05405166 |
| QLS32015 Qilu Pharmaceutical Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07018050, NCT07138209 |
| QLS4131 Qilu Pharmaceutical Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07933432, NCT07903636 |
| Selinexor Tablets Innovent Biologics (Suzhou) Co. Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07623798, NCT07569757 |
| bb2121 Celgene | Relapsed or refractory | Other or not recognised | Ph3 | NCT03651128 |
| CM313 Keymed Biosciences Co.Ltd | Relapsed or refractory | Other or not recognised | Ph3 | NCT07910903 |
| CM336 Keymed Biosciences Co.Ltd | Relapsed or refractory | Other or not recognised | Ph3 | NCT07910903 |
| CT-P44 Celltrion | Relapsed or refractory | Other or not recognised | Ph3 | NCT06952478 |
| Darzalex Faspro Celltrion | Relapsed or refractory | Other or not recognised | Ph3 | NCT06952478 |
| Dexamethasone tablets Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07569757 |
| F182112 single-agent Shandong New Time Pharmaceutical Co., LTD | Relapsed or refractory | Other or not recognised | Ph3 | NCT07579234 |
| InoPd CellCentric Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07772024 |
| Paracetamol / Acetaminophen Sanofi | Relapsed or refractory | Other or not recognised | Ph3 | NCT05405166 |
| Pom/dex GlaxoSmithKline | Relapsed or refractory | Other or not recognised | Ph3 | NCT04162210 |
| SG301 Injection Hangzhou Sumgen Biotech Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT06508983 |
| SVd Antengene Corporation | Relapsed or refractory | Other or not recognised | Ph3 | NCT04939142 |
| TQB2934 injection Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph3 | NCT07569757 |
| Vd Antengene Corporation | Relapsed or refractory | Other or not recognised | Ph3 | NCT04939142 |
| Xembify Grifols Therapeutics LLC | Relapsed or refractory | Other or not recognised | Ph3 | NCT05645107 |
| PI3K-beta Inhibitor GSK2636771 National Cancer Institute (NCI) | Relapsed or refractory | Other or not recognised | Ph2 | NCT02465060, NCT04439188, NCT04439149 |
| Busulfan University of California, Davis | Relapsed or refractory | Other or not recognised | Ph2 | NCT07759102, NCT02861417 |
| Forimtamig Hoffmann-La Roche | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06055075, NCT04557150 |
| HDP-101 Heidelberg Pharma AG | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04879043, NCT07529782 |
| tacrolimus City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph2 | NCT01163357, NCT02861417 |
| Thiotepa University of California, Davis | Relapsed or refractory | Other or not recognised | Ph2 | NCT07759102, NCT02861417 |
| Acetaminophen Sanofi | Relapsed or refractory | Other or not recognised | Ph2 | NCT06356571 |
| Aldesleukin AstraZeneca | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07681596 |
| Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06066359 |
| Allopurinol Masonic Cancer Center, University of Minnesota | Relapsed or refractory | Other or not recognised | Ph2 | NCT05805605 |
| AZD0120 AstraZeneca | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT05850234 |
| AZD4045 AstraZeneca | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07681596 |
| Belumosudil Sanofi | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04643002 |
| Belumosudil mesylate M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06105554 |
| Bone Marrow Cell Transplant Masonic Cancer Center, University of Minnesota | Relapsed or refractory | Other or not recognised | Ph2 | NCT05805605 |
| Clarithromycin Weill Medical College of Cornell University | Relapsed or refractory | Other or not recognised | Ph2 | NCT04302324 |
| CT0596 UCARsgen Biotech Limited | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07760454 |
| Evorpacept Sanofi | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04643002 |
| Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection Nanjing IASO Biotechnology Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07510100 |
| GEN3014 Genmab | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04824794 |
| GR1803 injection Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph2 | NCT06566547 |
| GSK3174998 GlaxoSmithKline | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04126200 |
| HP-001 Institute of Hematology & Blood Diseases Hospital, China | Relapsed or refractory | Other or not recognised | Ph2 | NCT07811986 |
| HuL001 HuniLife Biotechnology, Inc. | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07210047 |
| LBL-034 for Injection Nanjing Leads Biolabs Co.,Ltd | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT06049290 |
| MBS314 for Injection Beijing Mabworks Biotech Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT07911748 |
| OPC-415 Otsuka Pharmaceutical Co., Ltd. | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04649073 |
| Pegenzileukin Sanofi | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT04643002 |
| Pelareorep University of Southern California | Relapsed or refractory | Other or not recognised | Ph1/Ph2 | NCT05514990 |
Showing the 60 most advanced of 111 programs.
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Belantamab Mafodotin | PrECOG, LLC. | |
| Daratumumab | Janssen Research & Development, LLC | |
| Carfilzomib | Nantes University Hospital | |
| Elranatamab | Pfizer | |
| Bortezomib | National Cancer Institute (NCI) | |
| Isatuximab | University of Utah | |
| Teclistamab | European Myeloma Network B.V. | |
| Linvoseltamab | Regeneron Pharmaceuticals | |
| Lenalidomide | National Cancer Institute (NCI) | |
| Talquetamab | Noffar Bar | |
| Iberdomide | National Cancer Institute (NCI) | |
| Etentamig | AbbVie | |
| Cevostamab | Hoffmann-La Roche | |
| Mezigdomide | City of Hope Medical Center | |
| JNJ-79635322 | Janssen Research & Development, LLC | |
| AZD0120 | AstraZeneca | |
| Cilta-cel | Janssen Research & Development, LLC | |
| Ramantamig | Janssen Research & Development, LLC | |
| CM336 | Keymed Biosciences Co.Ltd | |
| Anitocabtagene Autoleucel | Kite, A Gilead Company | |
| QLS4131 | Qilu Pharmaceutical Co., Ltd. | |
| BMS-986393 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | |
| IgPro20 | CSL Behring | |
| Dabrafenib | Cancer Research UK | |
| BB2121 | Celgene | |
| CAEL-101 | Alexion Pharmaceuticals, Inc. | |
| QLS32015 | Qilu Pharmaceutical Co., Ltd. | |
| Xembify | Grifols Therapeutics LLC | |
| Equecabtagene Autoleucel Injection | Nanjing IASO Biotechnology Co., Ltd. | |
| CT-P44 | Celltrion |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07933432 A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131 No sites listed Decision brief → | Ph3 | Qilu Pharmaceutical Co., Ltd. | not yet recruiting | 2026-11-12 | 2029-12-14 |
| NCT07910903 Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph3 | Keymed Biosciences Co.Ltd | not yet recruiting | 2026-11-02 | 2030-05 |
| TRIlogy-6 · NCT07903272 A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible No sites listed Decision brief → | Ph3 | Janssen Research & Development, LLC | not yet recruiting | 2026-10-29 | 2037-01-11 |
| iMMagine-6 · NCT07903506 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma No sites listed Decision brief → | Ph3 | Kite, A Gilead Company | not yet recruiting | 2026-10-29 | 2039-03 |
| NCT07887984 Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma No sites listed Decision brief → | Ph2/Ph3 | Alliance for Clinical Trials in Oncology | not yet recruiting | 2026-10-22 | 2033-08-01 |
| iMMagine-4 · NCT07887672 A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma No sites listed Decision brief → | Ph3 | Kite, A Gilead Company | not yet recruiting | 2026-10-21 | 2042-02 |
| NCT07848672 Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization No sites listed Decision brief → | Ph2/Ph3 | The Affiliated People's Hospital of Ningbo University | not yet recruiting | 2026-09-30 | 2029-12-31 |
| DOMMINO-2 · NCT07772024 Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma Single-country: United States (1 site) Decision brief → | Ph3 | CellCentric Ltd. | recruiting | 2026-08-19 | 2029-11 |
| DURGA-5 · NCT07764978 Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT 15 countries, 36% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2026-08-14 | 2029-01-11 |
| AMMADINA · NCT07742215 A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA) 2 countries, 0% of sites in the US Decision brief → | Ph3 | Biocad | recruiting | 2026-08-03 | 2028-07 |
| TiTan · NCT07740486 A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease No sites listed Decision brief → | Ph3 | Polish Myeloma Consortium | not yet recruiting | 2026-07-31 | 2031-06 |
| DURGA-6 · NCT07735637 A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6). 18 countries, 40% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2026-07-30 | 2028-11-02 |
| NCT07732712 Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells No sites listed Decision brief → | Ph2/Ph3 | The Affiliated People's Hospital of Ningbo University | not yet recruiting | 2026-07-29 | 2028-12-31 |
| NCT07728188 A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma 13 countries, 36% of sites in the US Decision brief → | Ph3 | AbbVie | not yet recruiting | 2026-07-27 | 2033-02 |
| AugMMent · NCT07671287 GMMG-HD11/DSMM XXI/64007957MMY3010 No sites listed Decision brief → | Ph3 | University of Heidelberg Medical Center | not yet recruiting | 2026-06-26 | 2031-02-14 |
| TRIlogy-7 · NCT07665450 A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned 14 countries, 0% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2026-06-24 | 2030-09-04 |
| iFIT · NCT07649525 Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Single-country: United Kingdom (5 sites) Decision brief → | Ph3 | University of Leeds | recruiting | 2026-06-16 | 2033-06 |
| NCT07648264 Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies 11 countries, 28% of sites in the US Decision brief → | Ph3 | CSL Behring | recruiting | 2026-06-15 | 2029-09-27 |
| NCT07624513 D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Single-country: United States (3 sites) Decision brief → | Ph3 | Dana-Farber Cancer Institute | recruiting | 2026-06-03 | 2033-10-01 |
| NCT07623798 A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 Single-country: China (1 site) Decision brief → | Ph3 | Innovent Biologics (Suzhou) Co. Ltd. | recruiting | 2026-06-03 | 2029-05-31 |
| SIGMA · NCT07582432 A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma Single-country: United States (5 sites) Decision brief → | Ph3 | Grifols Biologicals, LLC | recruiting | 2026-05-12 | 2028-08-31 |
| NCT07579234 A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph3 | Shandong New Time Pharmaceutical Co., LTD | recruiting | 2026-05-12 | 2029-01-25 |
| NCT07569757 Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma Single-country: China (49 sites) Decision brief → | Ph3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | not yet recruiting | 2026-05-06 | 2028-12 |
| CEVOLUTION · NCT07555938 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma 18 countries, 13% of sites in the US Decision brief → | Ph3 | Hoffmann-La Roche | recruiting | 2026-04-29 | 2028-10-31 |
| TRIlogy-5 · NCT07518186 A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma 18 countries, 24% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2026-04-08 | 2029-04-29 |
| DETERMINE · NCT07440290 DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Single-country: United Kingdom (27 sites) Decision brief → | Ph2/Ph3 | Cancer Research UK | recruiting | 2026-02-27 | 2029-10 |
| LINKER-MM8 · NCT07428369 A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) No sites listed Decision brief → | Ph2/Ph3 | Regeneron Pharmaceuticals | withdrawn | 2026-02-23 | 2038-05-21 |
| LINKER-SMM2 · NCT07393282 A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) 6 countries, 27% of sites in the US Decision brief → | Ph3 | Regeneron Pharmaceuticals | recruiting | 2026-02-06 | 2033-07-27 |
| DURGA-4 · NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) 15 countries, 36% of sites in the US Decision brief → | Ph3 | AstraZeneca | recruiting | 2026-02-06 | 2028-06-14 |
| NCT07319897 68Ga-BCMA PET/CT in Multiple Myeloma Single-country: China (5 sites) Decision brief → | Ph2/Ph3 | Peking University First Hospital | recruiting | 2026-01-06 | 2027-12-30 |
| PrE1005 · NCT07285239 Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Single-country: United States (3 sites) Decision brief → | Ph3 | PrECOG, LLC. | recruiting | 2025-12-16 | 2031-11 |
| TRIlogy-4 · NCT07258511 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma 15 countries, 30% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2025-12-02 | 2028-12-12 |
| LINKER-MM5 · NCT07222761 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) 8 countries, 11% of sites in the US Decision brief → | Ph3 | Regeneron Pharmaceuticals | recruiting | 2025-10-30 | 2029-05-21 |
| NCT07138209 A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph3 | Qilu Pharmaceutical Co., Ltd. | recruiting | 2025-08-22 | 2027-12 |
| NCT07095452 A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant 4 countries, 35% of sites in the US Decision brief → | Ph2/Ph3 | AbbVie | recruiting | 2025-07-31 | 2041-03 |
| NCT06980480 A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma 17 countries, 11% of sites in the US Decision brief → | Ph3 | Takeda | recruiting | 2025-05-20 | 2028-09-11 |
| DREAMM 8 · NCT06956170 All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma Single-country: Japan (13 sites) Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2025-05-04 | 2024-05-27 |
| NCT06952478 A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma Single-country: Taiwan (1 site) Decision brief → | Ph3 | Celltrion | active not recruiting | 2025-05-01 | 2027-03-08 |
| ElLen · NCT06918002 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients 2 countries, 0% of sites in the US Decision brief → | Ph3 | Intergroupe Francophone du Myelome | recruiting | 2025-04-09 | 2036-05 |
| DREAMM 7 · NCT06868667 Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Single-country: Japan (16 sites) Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2025-03-11 | 2024-04-03 |
| DREAMM 7 · NCT06868654 China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma Single-country: China (11 sites) Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2025-03-11 | 2024-04-03 |
| DREAMM-10 · NCT06679101 A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) 24 countries, 17% of sites in the US Decision brief → | Ph3 | GlaxoSmithKline | recruiting | 2024-11-07 | 2031-04-28 |
| NCT06615479 A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) 31 countries, 16% of sites in the US Decision brief → | Ph3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | recruiting | 2024-09-26 | 2027-12-30 |
| NCT06514508 Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients Single-country: China (2 sites) Decision brief → | Ph3 | Guangzhou Gloria Biosciences Co., Ltd. | recruiting | 2024-07-23 | 2026-09-11 |
| NCT06508983 A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients Single-country: China (12 sites) Decision brief → | Ph3 | Hangzhou Sumgen Biotech Co., Ltd. | recruiting | 2024-07-19 | 2027-03-31 |
| FUMANBA-03 · NCT06464991 A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) 2 countries, 0% of sites in the US Decision brief → | Ph3 | Nanjing IASO Biotechnology Co., Ltd. | active not recruiting | 2024-06-18 | 2027-08 |
| iMMagine-3 · NCT06413498 A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma 15 countries, 39% of sites in the US Decision brief → | Ph3 | Kite, A Gilead Company | active not recruiting | 2024-05-14 | 2028-07 |
| NCT06395441 Wisconsin Ginseng for Decreasing Cancer Related Fatigue Single-country: United States (15 sites) Decision brief → | Ph3 | Mayo Clinic | recruiting | 2024-05-02 | 2027-12-30 |
| NCT06216158 Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma 2 countries, 0% of sites in the US Decision brief → | Ph3 | University of Heidelberg Medical Center | active not recruiting | 2024-01-22 | 2028-12 |
| MonumenTAL-6 · NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide 27 countries, 20% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2024-01-17 | 2026-04-01 |
| NCT06182774 Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma Single-country: Canada (31 sites) Decision brief → | Ph3 | Canadian Cancer Trials Group | recruiting | 2023-12-27 | 2032-01-31 |
| CERVINO · NCT06158841 Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma 25 countries, 28% of sites in the US Decision brief → | Ph3 | AbbVie | active not recruiting | 2023-12-06 | 2027-12 |
| NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) 27 countries, 37% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2023-11-30 | 2026-08-26 |
| NCT05827016 A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma 34 countries, 16% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | active not recruiting | 2023-04-24 | 2029-03-15 |
| LINKER-MM3 · NCT05730036 A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma 18 countries, 6% of sites in the US Decision brief → | Ph3 | Regeneron Pharmaceuticals | recruiting | 2023-02-15 | 2033-04-19 |
| EXCELL · NCT05645107 A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma 8 countries, 15% of sites in the US Decision brief → | Ph3 | Grifols Therapeutics LLC | recruiting | 2022-12-09 | 2029-08 |
| MagnetisMM-6 · NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant 25 countries, 19% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2022-11-21 | 2030-10-18 |
| MajesTEC-9 · NCT05572515 A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma 24 countries, 14% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2022-10-07 | 2025-10-13 |
| NCT05561387 Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment Single-country: United States (397 sites) Decision brief → | Ph3 | SWOG Cancer Research Network | recruiting | 2022-09-30 | 2031-05-30 |
| GEM21menos65 · NCT05558319 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Single-country: Spain (68 sites) Decision brief → | Ph3 | PETHEMA Foundation | recruiting | 2022-09-28 | 2027-04 |
| MajesTEC-7 · NCT05552222 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma 25 countries, 25% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2022-09-23 | 2031-04-30 |
| SUCCESSOR-2 · NCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) 27 countries, 16% of sites in the US Decision brief → | Ph3 | Bristol-Myers Squibb | active not recruiting | 2022-09-23 | 2026-09-28 |
| SUCCESSOR-1 · NCT05519085 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) 29 countries, 21% of sites in the US Decision brief → | Ph3 | Celgene | recruiting | 2022-08-29 | 2027-01-10 |
| MonumenTAL-3 · NCT05455320 A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment 18 countries, 19% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2022-07-13 | 2027-07-30 |
| NCT05438043 A Study of Daratumumab 17 countries, 8% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2022-06-29 | 2029-01-31 |
| IRAKLIA · NCT05405166 SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM 21 countries, 10% of sites in the US Decision brief → | Ph3 | Sanofi | active not recruiting | 2022-06-06 | 2024-11-06 |
| MagnetisMM-7 · NCT05317416 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant 27 countries, 11% of sites in the US Decision brief → | Ph3 | Pfizer | active not recruiting | 2022-04-07 | 2027-08-04 |
| MajesTEC-4 · NCT05243797 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation 25 countries, 19% of sites in the US Decision brief → | Ph3 | European Myeloma Network B.V. | active not recruiting | 2022-02-17 | 2028-04 |
| MajesTEC-3 · NCT05083169 A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma 21 countries, 10% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2021-10-19 | 2025-08-01 |
| MAGNETISMM-5 · NCT05020236 A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments 26 countries, 11% of sites in the US Decision brief → | Ph3 | Pfizer | recruiting | 2021-08-25 | 2026-02-26 |
| BENCH · NCT04939142 A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Single-country: China (33 sites) Decision brief → | Ph3 | Antengene Corporation | completed | 2021-06-25 | 2024-08-26 |
| CARTITUDE-5 · NCT04923893 A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy 26 countries, 14% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2021-06-11 | 2029-02-14 |
| NCT04566328 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial 2 countries, 99% of sites in the US Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | recruiting | 2020-09-28 | 2027-12-31 |
| NCT04512235 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) 19 countries, 29% of sites in the US Decision brief → | Ph3 | Alexion Pharmaceuticals, Inc. | active not recruiting | 2020-08-13 | 2025-04-08 |
| NCT04504825 A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) 19 countries, 29% of sites in the US Decision brief → | Ph3 | Alexion Pharmaceuticals, Inc. | active not recruiting | 2020-08-07 | 2025-05-10 |
| IsKia · NCT04483739 Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) 8 countries, 0% of sites in the US Decision brief → | Ph3 | European Myeloma Network B.V. | active not recruiting | 2020-07-23 | 2025-07-31 |
| DREAMM 8 · NCT04484623 Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma 18 countries, 4% of sites in the US Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2020-07-23 | 2024-01-29 |
| NCT04459416 Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma Single-country: United States (2 sites) Decision brief → | Ph3 | Memorial Sloan Kettering Cancer Center | active not recruiting | 2020-07-07 | 2024-07-02 |
| DREAMM 7 · NCT04246047 Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma 13 countries, 7% of sites in the US Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2020-01-29 | 2023-10-02 |
| CARTITUDE-4 · NCT04181827 A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma 16 countries, 22% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | active not recruiting | 2019-12-02 | 2024-05-01 |
| DREAMM-3 · NCT04162210 Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) 19 countries, 7% of sites in the US Decision brief → | Ph3 | GlaxoSmithKline | active not recruiting | 2019-11-14 | 2022-09-12 |
| KRdvsRd · NCT04096066 A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant Single-country: Italy (40 sites) Decision brief → | Ph3 | Fondazione EMN Italy Onlus | active not recruiting | 2019-09-19 | 2027-09-01 |
| DRAMMATIC · NCT04071457 S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration 2 countries, 99% of sites in the US Decision brief → | Ph3 | SWOG Cancer Research Network | active not recruiting | 2019-08-28 | 2032-09 |
| IFM2017_03 · NCT03993912 Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy Single-country: France (23 sites) Decision brief → | Ph3 | University Hospital, Lille | completed | 2019-06-21 | 2026-08-28 |
| NCT03937635 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma 2 countries, 99% of sites in the US Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | recruiting | 2019-05-06 | 2029-12-31 |
| AURIGA · NCT03901963 A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant 2 countries, 96% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | completed | 2019-04-03 | 2024-04-04 |
| MYELOCHOL · NCT03891914 Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma Single-country: France (1 site) Decision brief → | Ph3 | University Hospital, Bordeaux | completed | 2019-03-27 | 2023-01-27 |
| NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial 23 countries, 13% of sites in the US Decision brief → | Ph3 | AbbVie | active not recruiting | 2019-02-18 | 2027-08 |
| NCT03823534 Post-Op Pain Control for Prophylactic Intramedullary Nailing. Single-country: United States (1 site) Decision brief → | Ph3 | St. Louis University | recruiting | 2019-01-30 | 2026-12-31 |
| NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy 13 countries, 17% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | completed | 2018-08-29 | 2024-05-07 |
| KarMMa-3 · NCT03651128 Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) 13 countries, 58% of sites in the US Decision brief → | Ph3 | Celgene | completed | 2018-08-29 | 2026-04-13 |
| HaploMUD-RIC · NCT03595800 Extension of a Study of Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor to Younger Patients Eligible for Reduced-intensity Conditioning Regimen Single-country: France (1 site) Decision brief → | Ph3 | Institut Paoli-Calmettes | completed | 2018-07-23 | 2021-02-02 |
| IMROZ · NCT03319667 A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant 21 countries, 5% of sites in the US Decision brief → | Ph3 | Sanofi | active not recruiting | 2017-10-24 | 2027-04-05 |
| NCT03301220 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma 24 countries, 14% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | completed | 2017-10-04 | 2024-05-01 |
| IFM2013-04 · NCT01971658 Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) Single-country: France (62 sites) Decision brief → | Ph3 | Nantes University Hospital | completed | 2013-10-29 | 2015-08 |
| NCT01863550 Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma 2 countries, 99% of sites in the US Decision brief → | Ph3 | ECOG-ACRIN Cancer Research Group | active not recruiting | 2013-05-29 | 2026-12-31 |
| IMAJEM · NCT01309334 Imaging Young Myeloma (IMAgerie JEune Myélome) Single-country: France (17 sites) Decision brief → | Ph3 | Nantes University Hospital | completed | 2011-03-07 | 2013-09 |
| NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant 3 countries, 55% of sites in the US Decision brief → | Ph3 | Fred Hutchinson Cancer Center | completed | 2010-11-01 | 2016-10-08 |
| IFM/DFCI2009 · NCT01191060 Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years Single-country: France (68 sites) Decision brief → | Ph3 | University Hospital, Toulouse | completed | 2010-08-30 | 2018-11-30 |
| NCT01169337 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma 3 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2010-07-26 | 2019-01-25 |
| TT4B · NCT00734877 UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Single-country: United States (1 site) Decision brief → | Ph3 | University of Arkansas | active not recruiting | 2008-08-14 | 2027-09 |
| NCT00644228 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma 3 countries, 100% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2008-03-26 | 2015-11-05 |
| NCT00602641 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma 2 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2008-01-28 | 2014-01-18 |
| IFM2005-02 · NCT00430365 Maintenance Therapy Using Lenalidomide in Myeloma 3 countries, 0% of sites in the US Decision brief → | Ph3 | University Hospital, Toulouse | completed | 2007-02-01 | 2017-09 |
| NCT00114101 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant Single-country: United States (140 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2005-06-14 | 2012-12-31 |
| NCT00098475 Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Single-country: United States (138 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | active not recruiting | 2004-12-08 | 2008-11-30 |
| NCT07931391 SKCD in Early Relapsed/Refractory Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph2 | Beijing Chao Yang Hospital | recruiting | 2026-11-12 | 2030-03-31 |
| NCT07911748 A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma. No sites listed Decision brief → | Ph1/Ph2 | Beijing Mabworks Biotech Co., Ltd. | not yet recruiting | 2026-11-03 | 2027-12 |
| BEYOND-MM 002 · NCT07903636 QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-10-29 | 2027-12-01 |
| GEM-MeziDEL · NCT07901868 Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Single-country: Spain (20 sites) Decision brief → | Ph2 | PETHEMA Foundation | not yet recruiting | 2026-10-28 | 2031-12 |
| CAR-T 002 · NCT07895017 Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias Single-country: United States (1 site) Decision brief → | Ph2 | University of Virginia | not yet recruiting | 2026-10-26 | 2029-08 |
| NCT07891923 Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma Single-country: India (2 sites) Decision brief → | Ph2 | Tata Memorial Centre | recruiting | 2026-10-23 | 2029-05-05 |
| CARMic · NCT07842198 Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy Single-country: Denmark (1 site) Decision brief → | Ph2 | Zealand University Hospital | not yet recruiting | 2026-09-25 | 2029-12-31 |
| CAREMM-010 · NCT07830485 CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-09-21 | 2029-04-15 |
| CAREMM-009 · NCT07828522 F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma No sites listed Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-09-18 | 2027-10-09 |
| NCT07825064 Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma Single-country: Germany (5 sites) Decision brief → | Ph2 | Hoffmann-La Roche | recruiting | 2026-09-17 | 2029-04-13 |
| BEYOND-MM 001 · NCT07811986 HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-09-10 | 2027-12-31 |
| HRMM-001 · NCT07789522 Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma No sites listed Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-08-27 | 2027-10-09 |
| NCT07771361 BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma No sites listed Decision brief → | Ph2 | Luminary Therapeutics | not yet recruiting | 2026-08-18 | 2030-12 |
| NCT07764861 A Open-Label Phase in Participants With Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph2 | Innovent Biologics (Suzhou) Co. Ltd. | not yet recruiting | 2026-08-14 | 2026-12-31 |
| NCT07760454 A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma Single-country: China (2 sites) Decision brief → | Ph1/Ph2 | UCARsgen Biotech Limited | recruiting | 2026-08-12 | 2030-12-31 |
| ADAPTATION · NCT07757412 Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma. 4 countries, 0% of sites in the US Decision brief → | Ph2 | Odense University Hospital | not yet recruiting | 2026-08-11 | 2029-01-01 |
| REBEL · NCT07748689 Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. No sites listed Decision brief → | Ph2 | Polish Myeloma Consortium | not yet recruiting | 2026-08-06 | 2033-03 |
| FAPIPET · NCT07705074 FAPI PET Imaging - An Exploratory Study Single-country: Switzerland (5 sites) Decision brief → | Ph1/Ph2 | Martin Huellner | not yet recruiting | 2026-07-15 | 2029-09 |
| NCT07695740 Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma Single-country: China (1 site) Decision brief → | Ph2 | Excyte Biopharma Ltd | not yet recruiting | 2026-07-10 | 2030-12 |
| NCT07689058 CAR-T in Relapsed/Refractory Multiple Myeloma Single-country: Pakistan (2 sites) Decision brief → | Ph2 | Dr. Zaineb Akram | recruiting | 2026-07-08 | 2027-12-31 |
| AL-005 · NCT07687004 Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-07-07 | 2027-08-01 |
| NCT07681596 A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma 2 countries, 83% of sites in the US Decision brief → | Ph1/Ph2 | AstraZeneca | recruiting | 2026-07-02 | 2031-03-06 |
| NCT07657312 Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Single-country: United States (1 site) Decision brief → | Ph2 | Naresh Bumma | recruiting | 2026-06-18 | 2027-12-31 |
| CAREMM-011 · NCT07652905 CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2026-06-17 | 2029-06-30 |
| CAREMM-013 · NCT07648459 CM336-SOC for Dynamically High-Risk Multiple Myeloma Study No sites listed Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-06-15 | 2027-07-09 |
| CORE-MM · NCT07637578 A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Single-country: United States (6 sites) Decision brief → | Ph2 | SCRI Development Innovations, LLC | recruiting | 2026-06-10 | 2029-10 |
| NCT07638683 A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL). Single-country: China (1 site) Decision brief → | Ph2 | Shanghai Zhongshan Hospital | recruiting | 2026-06-10 | 2028-07-30 |
| BELAMI · NCT07612787 A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma Single-country: France (30 sites) Decision brief → | Ph1/Ph2 | Centre Hospitalier Universitaire de Saint Etienne | not yet recruiting | 2026-05-29 | 2028-01-01 |
| DREAMM-16 · NCT07614360 Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma No sites listed Decision brief → | Ph2 | GlaxoSmithKline | not yet recruiting | 2026-05-29 | 2029-02-28 |
| NCT07605416 Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Single-country: United States (11 sites) Decision brief → | Ph2 | National Cancer Institute (NCI) | recruiting | 2026-05-26 | 2032-11-06 |
| IsaIberVD · NCT07601100 Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Single-country: United States (2 sites) Decision brief → | Ph1/Ph2 | Dana-Farber Cancer Institute | not yet recruiting | 2026-05-22 | 2029-07-01 |
| CONQUISTADOR · NCT07600151 Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Single-country: Germany (1 site) Decision brief → | Ph1/Ph2 | Universitätsklinikum Hamburg-Eppendorf | not yet recruiting | 2026-05-20 | 2036-09-30 |
| TRI Pro · NCT07589634 A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma 10 countries, 15% of sites in the US Decision brief → | Ph2 | Janssen Research & Development, LLC | recruiting | 2026-05-15 | 2027-12-31 |
| CAREMM-012 · NCT07585760 CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2026-05-14 | 2028-05-01 |
| NCT07567014 Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS Single-country: United States (3 sites) Decision brief → | Ph2 | NYU Langone Health | not yet recruiting | 2026-05-05 | 2028-05-31 |
| ADAPT-HEM · NCT07523555 Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Beijing Biotech | recruiting | 2026-04-13 | 2027-03-14 |
| NCT07509086 IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia Single-country: China (1 site) Decision brief → | Ph2 | The First Hospital of Jilin University | recruiting | 2026-04-03 | 2028-07-15 |
| FUMANBA-04 · NCT07510100 Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma Single-country: Japan (3 sites) Decision brief → | Ph1/Ph2 | Nanjing IASO Biotechnology Co., Ltd. | not yet recruiting | 2026-04-03 | 2029-08-31 |
| NCT07485647 Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing Single-country: United States (1 site) Decision brief → | Ph2 | Eden Biltibo | recruiting | 2026-03-20 | 2028-05 |
| NCT07479979 Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Natalie Callander | recruiting | 2026-03-18 | 2027-07 |
| MSTH-CAR001 · NCT07477912 Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma Single-country: Belarus (1 site) Decision brief → | Ph1/Ph2 | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | recruiting | 2026-03-17 | 2028-02-01 |
| NCT07463807 Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | National Cancer Institute (NCI) | recruiting | 2026-03-11 | 2029-03-31 |
| NCT07455851 A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma 2 countries, 0% of sites in the US Decision brief → | Ph1/Ph2 | Regeneron Pharmaceuticals | recruiting | 2026-03-06 | 2033-09-30 |
| NCT07454187 To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma Single-country: China (4 sites) Decision brief → | Ph1/Ph2 | Hangzhou Sumgen Biotech Co., Ltd. | recruiting | 2026-03-06 | 2027-09-30 |